Arcutis Biotherapeutics (ARQT) Stock Forecast & Price Target

Compare

941 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ARQT Analyst Ratings

Strong Buy

5 Buy

1 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Arcutis

Biotherapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ARQT Stock 12 Month Forecast

Average Price Target

$29.50

▲(0.10% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Arcutis Biotherapeutics in the last 3 months. The average price target is $29.50 with a high forecast of $37.00 and a low forecast of $21.00. The average price target represents a 0.10% change from the last price of $29.47.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","38":"$38","14.75":"$14.75","22.5":"$22.5","30.25":"$30.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$37.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,14.75,22.5,30.25,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.31,26.209230769230768,27.108461538461537,28.007692307692306,28.906923076923075,29.806153846153844,30.705384615384617,31.604615384615386,32.503846153846155,33.403076923076924,34.30230769230769,35.20153846153846,36.10076923076923,{"y":37,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.31,25.63230769230769,25.954615384615384,26.276923076923076,26.59923076923077,26.92153846153846,27.243846153846153,27.566153846153846,27.888461538461538,28.21076923076923,28.533076923076923,28.855384615384615,29.177692307692308,{"y":29.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.31,24.978461538461538,24.646923076923077,24.315384615384616,23.98384615384615,23.65230769230769,23.32076923076923,22.98923076923077,22.657692307692308,22.326153846153847,21.994615384615386,21.663076923076922,21.33153846153846,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.67,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.93,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.24,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.65,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.29,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.31,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$37.00

Average Price Target$29.50

Lowest Price Target$21.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Uy Ear

Mizuho Securities

$32→$37

Buy

25.55%

Upside

Reiterated

11/26/25

Mizuho Securities Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)

Douglas Tsao

H.C. Wainwright

$24.23→$30

Buy

1.80%

Upside

Reiterated

11/09/25

H.C. Wainwright Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT)

Richard Law CFA

Goldman Sachs

$19→$29

Hold

-1.59%

Downside

Reiterated

10/30/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Arcutis Biotherapeutics (NASDAQ: ARQT), Encompass Health (NYSE: EHC) and Glaukos (NYSE: GKOS)

Serge Belanger

Needham

$22→$30

Buy

1.80%

Upside

Reiterated

10/29/25

Arcutis Biotherapeutics: Strong Q3 Performance and Strategic Growth Drive Buy RatingWe maintain our Buy rating and adjust our $PT to $30 (from $22) to reflect the strong 3Q25 performance (higher sales and lower OpEx) and the initial 2026 guidance.

Tyler Van Buren

TD Cowen

$25→$30

Buy

1.80%

Upside

Reiterated

10/28/25

Arcutis Biotherapeutics: Strong Sales and Growth Prospects Justify Buy Rating

Judah Frommer

Morgan Stanley

$21

Buy

-28.74%

Downside

Reiterated

10/16/25

Morgan Stanley Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)We establish an OW rating as we see continued room for ARQT to rise based on strong execution with the Zoryve/roflumilast pipeline.

Seamus Fernandez

Guggenheim

$29

Buy

-1.59%

Downside

Reiterated

08/06/25

Guggenheim Sticks to Its Buy Rating for Arcutis Biotherapeutics (ARQT)

Kambiz Yazdi

BTIG

$20→$23

Buy

-21.95%

Downside

Reiterated

07/21/25

Jefferies Sticks to Its Buy Rating for Arcutis Biotherapeutics (ARQT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Uy Ear

Mizuho Securities

$32→$37

Buy

25.55%

Upside

Reiterated

11/26/25

Mizuho Securities Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)

Douglas Tsao

H.C. Wainwright

$24.23→$30

Buy

1.80%

Upside

Reiterated

11/09/25

H.C. Wainwright Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT)

Richard Law CFA

Goldman Sachs

$19→$29

Hold

-1.59%

Downside

Reiterated

10/30/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Arcutis Biotherapeutics (NASDAQ: ARQT), Encompass Health (NYSE: EHC) and Glaukos (NYSE: GKOS)

Serge Belanger

Needham

$22→$30

Buy

1.80%

Upside

Reiterated

10/29/25

Tyler Van Buren

TD Cowen

$25→$30

Buy

1.80%

Upside

Reiterated

10/28/25

Arcutis Biotherapeutics: Strong Sales and Growth Prospects Justify Buy Rating

Judah Frommer

Morgan Stanley

$21

Buy

-28.74%

Downside

Reiterated

10/16/25

Seamus Fernandez

Guggenheim

$29

Buy

-1.59%

Downside

Reiterated

08/06/25

Guggenheim Sticks to Its Buy Rating for Arcutis Biotherapeutics (ARQT)

Kambiz Yazdi

BTIG

$20→$23

Buy

-21.95%

Downside

Reiterated

07/21/25

Jefferies Sticks to Its Buy Rating for Arcutis Biotherapeutics (ARQT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcutis Biotherapeutics

1 Month

xxx

Success Rate

22/46 ratings generated profit

Average Return

+5.26%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 47.83% of your transactions generating a profit, with an average return of +5.26% per trade.

3 Months

xxx

Success Rate

23/46 ratings generated profit

Average Return

+5.03%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +5.03% per trade.

1 Year

Serge BelangerNeedham

Success Rate

15/21 ratings generated profit

Average Return

+67.15%

reiterated a buy rating 2 months ago

Copying Serge Belanger's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +67.15% per trade.

2 Years

xxx

Success Rate

16/21 ratings generated profit

Average Return

+161.43%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 76.19% of your transactions generating a profit, with an average return of +161.43% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARQT Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ARQT has received 11 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. ARQT average Analyst price target in the past 3 months is 29.50.

Each month's total comprises the sum of three months' worth of ratings.

ARQT Financial Forecast

ARQT Earnings Forecast

Next quarter’s earnings estimate for ARQT is $0.07 with a range of -$0.05 to $0.17. The previous quarter’s EPS was $0.06. ARQT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ARQT has Performed in-line its overall industry.

ARQT Sales Forecast

Next quarter’s sales forecast for ARQT is $110.28M with a range of $107.00M to $113.00M. The previous quarter’s sales results were $99.22M. ARQT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ARQT has Performed in-line its overall industry.

ARQT Stock Forecast FAQ

What is ARQT’s average 12-month price target, according to analysts?

Based on analyst ratings, Arcutis Biotherapeutics’s 12-month average price target is 29.50.

What is ARQT’s upside potential, based on the analysts’ average price target?

Arcutis Biotherapeutics has 0.10% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ARQT a Buy, Sell or Hold?

Arcutis Biotherapeutics has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.

What is Arcutis Biotherapeutics’s price target?

The average price target for Arcutis Biotherapeutics is 29.50. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $37.00 ,the lowest forecast is $21.00. The average price target represents 0.10% Increase from the current price of $29.47.

What do analysts say about Arcutis Biotherapeutics?

Arcutis Biotherapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of ARQT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Arcutis Biotherapeutics (ARQT) Stock Forecast & Price Target

ARQT Analyst Ratings

ARQT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Arcutis Biotherapeutics

ARQT Analyst Recommendation Trends

ARQT Financial Forecast

ARQT Earnings Forecast

ARQT Sales Forecast

ARQT Stock Forecast FAQ

Detailed List of Analyst Forecasts